Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal. All content is subject to the portal’s Community Content Guidelines.
Which Enzyme Is Missing in Fabry Disease? — DECODE No. 1
I'm a single enzyme. When I go missing, a fatty molecule quietly piles up inside your cells — silently, for years — until it starts to damage kidneys, heart, and nerves.
My name begins with the first letter of the Greek alphabet.
Who am I? Drop your guess in the comments — the answer posts with DECODE No. 2.
Follow the whole series: https://b2f.bz/5k9n3
@Brian Christie @Neva W...more
The top symptoms needing to be addressed for Fabry disease
We asked 51 people living with Fabry disease a single question: if a new treatment could improve just one symptom, which would matter most to your quality of life?
A snap shot of the results are in the figure and they matter to how we think about where a new therapy creates value.
Neuropathic pain of the feet and hands came first at 31%, followed by fatigue at 22% and gastrointestinal symptoms at ...more
Biotech Funding Portal debut at BIO
Biotech Social debuted the BioTech Funding Portal at the BLPN Field of Dreams Summit in San Diego at the BIO2026 meeting. Glafabra Therapeutics is proud to be one of the first companies on the platform.
Starting with a Testing the Waters campaign under Regulation Crowdfunding, retail and accredited investors alike can get an early look at companies they can follow before a formal raise opens.
Soo...more
Welcome to the BioTech Funding Portal
We’re so glad you’re here! If we seem new to you, it is because we are. We are also a new concept in crowdfunding, built exclusively for the life sciences. Our mission is to build a strong community around the scientists and entrepreneurs working to bring life-altering solutions to patients. We believe in the power of the collective to help turn crucial treatments and diagnostics into reality.
As ...more
Energesis’ Energy Expenditure Approach to Obesity: Brown Fat, GLP-1s, and the Competitive Landscape
GLP-1 drugs such as semaglutide and tirzepatide have changed the obesity treatment landscape. They have helped many people lose meaningful weight and have made obesity one of the most important areas in medicine today.
But we do not believe they are the end of the story.
The GLP-1 therapies work by reducing appetite and food intake. This can be effective, but it addresses only one side of the body-w...more
LSDs + protein deficiency: a $13B Market and Rising
The Fabry Market Is Bigger Than the Headlines, and the Platform Behind It Is Bigger Still
Every few months a new acquisition reminds the market that lysosomal storage disorders are quietly one of the most durable franchises in rare disease. BioMarin's $4.8B acquisition of Amicus in April 2026 was the latest. So it is worth doing the arithmetic out loud, from primary sources, on exactly how large t...more
Cultivating an ecosystem of trust through principled decision-making
Glafabra Therapeutics Receives FDA Acceptance for Face-to-Face INTERACT Meeting for GT-GLA-S03, Its Cell-Based Gene Therapy for Fabry Disease
Glafabra granted a face-to-face INTERACT meeting slated to occur July 16, 2026.
We will be discussing with the FDA key questions that will set the development path of our GT-GLA-S03 cell-based gene therapy for Fabry in its journey towards the market.
This milestone achievement was only made possible with the amazing contributions of the internal team and our contractors. Many thanks to Elizabeth W
